Preclinical evidence indicates that ICD inducing cytotoxicants (such as oxaliplatin and cyclophosphamide, especially if combined) can sensitize NSCLC to CTLA-4/PD-1 blockade31. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.